Rgm Capital Trimmed Its Monotype Imaging Holdings In (TYPE) Holding by $864,600; Market Valuation Declined; As Valeant Pharmaceuticals Intl (VRX) Market Value Rose, Shareholder Saba Capital Management LP Trimmed Holding by $34.82 Million

June 18, 2018 - By Peter Erickson

Monotype Imaging Holdings Inc. (NASDAQ:TYPE) Logo

Boaz Weinstein decreased its stake in Valeant Pharmaceuticals Intl (VRX) by 90.3% based on its latest 2018Q1 regulatory filing with the SEC. Saba Capital Management Lp sold 2.32 million shares as the company’s stock rose 17.86% while stock markets declined. The hedge fund run by Boaz Weinstein held 249,300 shares of the health care company at the end of 2018Q1, valued at $3.97M, down from 2.57 million at the end of the previous reported quarter. Saba Capital Management Lp who had been investing in Valeant Pharmaceuticals Intl for a number of months, seems to be less bullish one the $9.38B market cap company. The stock increased 0.22% or $0.06 during the last trading session, reaching $26.86. About 6.07 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 73.89% since June 18, 2017 and is uptrending. It has outperformed by 61.32% the S&P500. Some Historical VRX News: 08/03/2018 – Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis; 12/04/2018 – Rifaximin-α Reduces the lncidence of Sepsis and All-Cause Admissions Whilst on the Liver Transplant Waiting List i and Hospital Admissions; 12/04/2018 – VALEANT – TRIBUNAL ISSUED A RULING REJECTING COSMO’S CLAIMS IN THEIR ENTIRETY RELATED TO UCERIS ARBITRATION; 08/05/2018 – VALEANT – NEW CORPORATE BRAND IDENTITY WILL INCLUDE NEW IMAGERY AND WEB SITE, AND WILL TRADE UNDER A NEW SYMBOL, BHC; 12/04/2018 – newsbox.ch/ Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant; 17/05/2018 – VALEANT REPORTS LAUNCH OF PRIVATE OFFERING OF NOTES & UPSIZE OF; 26/03/2018 – VALEANT & ONE OF UNITS REPORT EARLY TENDER RESULTS & EARLY; 02/05/2018 – KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira™ (phentermine hydrochloride USP) 8 mg Tablets, CIV; 18/05/2018 – Orexigen’s Contrave Sales Fall; Obesity Market Down 2%; 14/03/2018 – REG-Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA

Robert G. Moses decreased its stake in Monotype Imaging Holdings In (TYPE) by 1.12% based on its latest 2018Q1 regulatory filing with the SEC. Rgm Capital Llc sold 39,300 shares as the company’s stock declined 10.06% with the market. The hedge fund run by Robert G. Moses held 3.45 million shares of the edp services company at the end of 2018Q1, valued at $77.55 million, down from 3.49M at the end of the previous reported quarter. Rgm Capital Llc who had been investing in Monotype Imaging Holdings In for a number of months, seems to be less bullish one the $877.61M market cap company. The stock decreased 0.68% or $0.15 during the last trading session, reaching $21.8. About 173,592 shares traded. Monotype Imaging Holdings Inc. (NASDAQ:TYPE) has risen 10.28% since June 18, 2017 and is uptrending. It has underperformed by 2.29% the S&P500. Some Historical TYPE News: 27/04/2018 – MONOTYPE IMAGING HOLDINGS INC – SEES FY 2018 NON-GAAP EARNINGS PER DILUTED SHARE OF $0.47 — $0.52; 27/04/2018 – Monotype Imaging Sees 2Q EPS 0c-EPS 3c; 04/04/2018 – MONOTYPE IMAGING HOLDINGS INC – APPOINTED EILEEN CAMPBELL AND DENISE WARREN AS NEW INDEPENDENT DIRECTORS, EFFECTIVE IMMEDIATELY; 04/04/2018 – MONOTYPE NAMES PAMELA LENEHAN CHAIR OF BOARD; 13/03/2018 – Meet Monotype’s New Modern Branding Typefaces: Madera and Unitext; 27/04/2018 – MONOTYPE IMAGING HOLDINGS INC – SEES FY 2018 GAAP EARNINGS PER DILUTED SHARE $0.10 — $0.15; 04/04/2018 – Monotype Imaging Names Eileen Campbell and Denise Warren Directors; 27/04/2018 – Monotype Imaging 1Q Loss/Shr 3c; 27/04/2018 – MONOTYPE IMAGING HOLDINGS INC – SEES FY 2018 REVENUE OF $243.0 MLN – $251.0 MLN; 27/04/2018 – Monotype Imaging Sees 2Q Adj EPS 9c-Adj EPS 12c

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on August, 14. They expect $0.80 EPS, down 23.81% or $0.25 from last year’s $1.05 per share. VRX’s profit will be $279.43M for 8.39 P/E if the $0.80 EPS becomes a reality. After $0.89 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -10.11% negative EPS growth.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Schaeffersresearch.com which released: “Options Bulls Blitz Booming Valeant Pharmaceuticals Stock” on June 05, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on June 15, 2018, Seekingalpha.com published: “Valeant: Much Ado About Nothing” on May 21, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Finance.Yahoo.com and their article: “Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play” published on June 15, 2018 as well as Seekingalpha.com‘s news article titled: “Valeant Pharmaceuticals Can Still Go Higher – Cramer’s Lightning Round (5/21/18)” with publication date: May 22, 2018.

Saba Capital Management Lp, which manages about $7.93B and $1.80B US Long portfolio, upped its stake in Prudential Glb Sht Dur Hg Yl (GHY) by 461,635 shares to 696,448 shares, valued at $9.67M in 2018Q1, according to the filing. It also increased its holding in Donnelley R R & Sons Co by 49,747 shares in the quarter, for a total of 171,846 shares, and has risen its stake in Credit Suisse Asset Mgmt Inc (CIK).

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 have Buy rating, 5 Sell and 14 Hold. Therefore 32% are positive. Valeant Pharmaceuticals Intl had 171 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Sector Perform” rating in Thursday, March 23 report. Deutsche Bank maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Monday, November 14 with “Hold” rating. The rating was maintained by RBC Capital Markets with “Hold” on Monday, October 2. IBC downgraded the shares of VRX in report on Tuesday, October 20 to “Sector Perform” rating. Deutsche Bank maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Friday, October 14 with “Hold” rating. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. The stock has “Neutral” rating by Rodman & Renshaw on Thursday, November 10. As per Monday, December 4, the company rating was maintained by BTIG Research. The company was maintained on Tuesday, May 8 by Cantor Fitzgerald. RBC Capital Markets maintained the shares of VRX in report on Monday, December 14 with “Outperform” rating.

Since March 8, 2018, it had 4 insider buys, and 0 sales for $1.20 million activity. $481,500 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) was bought by PAPA JOSEPH C on Tuesday, March 13. On Tuesday, March 13 the insider Herendeen Paul bought $241,470.

Investors sentiment increased to 1.06 in 2018 Q1. Its up 0.09, from 0.97 in 2017Q4. It improved, as 29 investors sold VRX shares while 90 reduced holdings. 52 funds opened positions while 74 raised stakes. 167.32 million shares or 1.38% less from 169.66 million shares in 2017Q4 were reported. Baystate Wealth Mngmt Ltd Liability Corp holds 152 shares. Valueact Limited Partnership reported 18.01M shares stake. Texas-based Utd Ser Automobile Association has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 173,004 were reported by State Street. Stanley Capital Mgmt Ltd Liability reported 318,400 shares. Advisory Svcs accumulated 56 shares. Renaissance Technology Limited Liability Corp reported 4.98M shares or 0.09% of all its holdings. Alliancebernstein Limited Partnership, a New York-based fund reported 110,743 shares. Dimensional Fund LP stated it has 5.70M shares or 0.04% of all its holdings. First Manhattan Co invested in 0% or 34 shares. Fincl Bank Of New York Mellon Corp reported 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Goldman Sachs Group, New York-based fund reported 2.87 million shares. 11,900 were accumulated by Old Mutual Customised Solutions (Proprietary) Limited. Biglari reported 395,000 shares stake. Ww holds 1.10M shares or 0% of its portfolio.

Analysts await Monotype Imaging Holdings Inc. (NASDAQ:TYPE) to report earnings on July, 27. They expect $0.06 EPS, up 50.00% or $0.02 from last year’s $0.04 per share. TYPE’s profit will be $2.42 million for 90.83 P/E if the $0.06 EPS becomes a reality. After $0.13 actual EPS reported by Monotype Imaging Holdings Inc. for the previous quarter, Wall Street now forecasts -53.85% negative EPS growth.

Investors sentiment increased to 1.66 in 2018 Q1. Its up 0.55, from 1.11 in 2017Q4. It improved, as 19 investors sold TYPE shares while 28 reduced holdings. 31 funds opened positions while 47 raised stakes. 37.05 million shares or 0.85% more from 36.73 million shares in 2017Q4 were reported. First Trust Advisors LP holds 13,188 shares. 86,974 were reported by Rice Hall James And Associate Ltd Limited Liability Company. Barclays Public Ltd reported 0% stake. Goldman Sachs Grp owns 1.59 million shares. Robeco Institutional Asset Mgmt Bv reported 0% stake. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 2,019 shares or 0% of the stock. Bankshares Of New York Mellon has 591,232 shares. Convergence Invest Prns Limited Liability Co owns 54,230 shares for 0.16% of their portfolio. Swiss Bancshares stated it has 73,500 shares. Mason Street Advsr Limited Liability Corp holds 11,530 shares. Commercial Bank Of Montreal Can reported 1,984 shares. The New Jersey-based Bessemer Grp Incorporated has invested 0% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Ironwood Limited Liability Com reported 0.01% stake. Federated Investors Incorporated Pa invested 0% in Monotype Imaging Holdings Inc. (NASDAQ:TYPE). Winslow Evans & Crocker reported 100 shares or 0% of all its holdings.

Among 7 analysts covering Monotype Imaging Holdings (NASDAQ:TYPE), 4 have Buy rating, 2 Sell and 1 Hold. Therefore 57% are positive. Monotype Imaging Holdings had 9 analyst reports since September 8, 2015 according to SRatingsIntel. The company was maintained on Friday, February 12 by Dougherty & Company. The rating was downgraded by Zacks to “Sell” on Tuesday, September 8. The firm earned “Buy” rating on Tuesday, February 20 by B. Riley & Co. The stock has “Buy” rating by FBR Capital on Tuesday, June 12. The stock of Monotype Imaging Holdings Inc. (NASDAQ:TYPE) earned “Buy” rating by FBR Capital on Tuesday, February 20. As per Wednesday, May 25, the company rating was initiated by Ladenburg Thalmann. J.P. Morgan downgraded Monotype Imaging Holdings Inc. (NASDAQ:TYPE) rating on Tuesday, December 12. J.P. Morgan has “Sell” rating and $24.0 target. The stock of Monotype Imaging Holdings Inc. (NASDAQ:TYPE) earned “Neutral” rating by JP Morgan on Thursday, January 12.

Rgm Capital Llc, which manages about $775.24 million and $1.14B US Long portfolio, upped its stake in Comscore Inc (NASDAQ:SCOR) by 531,600 shares to 3.09M shares, valued at $74.34 million in 2018Q1, according to the filing. It also increased its holding in Imperva Inc (NYSE:IMPV) by 476,660 shares in the quarter, for a total of 1.76 million shares, and has risen its stake in Liveperson Inc (NASDAQ:LPSN).

Since January 11, 2018, it had 0 insider buys, and 9 sales for $2.48 million activity. Martin Steven R sold 24,700 shares worth $543,400. Shares for $29,675 were sold by Dunlap Janet M on Friday, February 16. 1,000 shares were sold by Semmes Benjamin W.L. III, worth $21,000 on Tuesday, May 15.

Another recent and important Monotype Imaging Holdings Inc. (NASDAQ:TYPE) news was published by Businesswire.com which published an article titled: “Monotype to Present at Baird’s 2018 Global Consumer, Technology & Services Conference” on June 04, 2018.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>